COMMUNIQUÉS West-GlobeNewswire

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

14/08/2024 - 22:35

MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

14/08/2024 - 22:30

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release [...]

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

14/08/2024 - 22:30

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results [...]

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

14/08/2024 - 22:30

NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today [...]

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

14/08/2024 - 22:25

Company to host conference call on August 15, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]

PetVivo Reports Reports Fiscal Q1 2025 Results

14/08/2024 - 22:25

Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering [...]

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million

14/08/2024 - 22:25

LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer [...]

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

14/08/2024 - 22:21

Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) program Early indication of monotherapy activity in [...]

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14/08/2024 - 22:16

Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management [...]

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

14/08/2024 - 22:10

GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

14/08/2024 - 22:05

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and [...]

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

14/08/2024 - 22:05

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

14/08/2024 - 22:05

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 [...]

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

14/08/2024 - 22:05

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 [...]

Seer Appoints Nicolas Roelofs to its Board of Directors

14/08/2024 - 22:05

REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas [...]

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

14/08/2024 - 22:05

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened [...]

STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

14/08/2024 - 22:05

HORSHAM, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Windtree Announces New Additions and Changes to Its Board of Directors

14/08/2024 - 22:05

WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

14/08/2024 - 22:05

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash [...]